There is robust clinical evidence to demonstrate that PARPi significantly reduces the risk of disease recurrence and provides a clinically meaningful extension of overall survival in BRCA germline pathogenic variant carriers with high-risk early HR-positive HER2-negative BC. Here, ERBB2 is linked to breast cancer.